GlassScriptPhysician profile
Ryan C Frazine
NPI 1548339070
$8,630.17
in general payments reported to CMS, 2019-2025
45 companies · $1,909 in 2025
The $1,909 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $336 · 2021: $488 · 2022: $1,118 · 2023: $1,359 · 2024: $1,956 · 2025: $1,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,224.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,346.69 | 2019-2025 | |
| Novo Nordisk INC | $1,345.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $954.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $799.41 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $614.25 | 2019-2025 | Jardiance |
| Pfizer INC. | $606.87 | 2019-2025 | |
| Amgen INC. | $361.41 | 2019-2025 | Repatha, Otezla, Evenity |
| Lundbeck LLC | $224.86 | 2022-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $190.74 | 2019-2025 | |
| Axsome Therapeutics, INC. | $168.21 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $151.67 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $150.07 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $143.84 | 2019-2024 | Spravato, Xarelto |
| Sanofi-Aventis U.S. LLC | $140.38 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.41 | 2019-2025 | Xifaxan |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Frazine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.